Myasthenia Gravis Treatment Market Size, Share, Growth Analysis, By Treatment (Revenue, USD Million, 2015 - 2026)(Medication, Surgery, Others), By End-Use (Revenue, USD Million, 2015 - 2026)(Hospitals, Clinics, Others), By Regional (Revenue, USD Million, 2015 - 2026)(North America, The U.S., Canada, Europe) - Industry Forecast 2024-2031

Report ID: UCMIG35I2237 | Region: Global | Published Date: Upcoming |
Pages: 165 |Tables: 0 |Figures: 0

Myasthenia Gravis Treatment Market Insights

Market Overview:

Commencing at an estimation of USD 1.16 billion in 2018, the global market for myasthenia gravis (MG) treatment is poised to undergo substantial expansion, projected to uphold an impressive Compound Annual Growth Rate (CAGR) of 7.5% throughout the forecast period. This ascending trajectory is underpinned by a convergence of pivotal factors. Chief among them is the escalating uptake of immunotherapies, a trend bolstered by the approval of promising drugs that offer renewed optimism for MG patients. Furthermore, the emergence of biologics in the treatment landscape has spurred innovative avenues for managing this condition. Adding to this dynamic landscape is the growing awareness surrounding rare diseases, including myasthenia gravis, which collectively coalesce to drive the market's evolution, enabling improved care for affected individuals worldwide.

Myasthenia Gravis Treatment Market, Forecast & Y-O-Y Growth Rate, 2020 - 2028
ForecastGrowthRate
To get more reports on the above market click here to
GET FREE SAMPLE

This report is being written to illustrate the market opportunity by region and by segments, indicating opportunity areas for the vendors to tap upon. To estimate the opportunity, it was very important to understand the current market scenario and the way it will grow in future.

Production and consumption patterns are being carefully compared to forecast the market. Other factors considered to forecast the market are the growth of the adjacent market, revenue growth of the key market vendors, scenario-based analysis, and market segment growth.

The market size was determined by estimating the market through a top-down and bottom-up approach, which was further validated with industry interviews. Considering the nature of the market we derived the Pharmaceuticals by segment aggregation, the contribution of the Pharmaceuticals in Pharmaceuticals, Biotechnology & Life Sciences and vendor share.

To determine the growth of the market factors such as drivers, trends, restraints, and opportunities were identified, and the impact of these factors was analyzed to determine the market growth. To understand the market growth in detail, we have analyzed the year-on-year growth of the market. Also, historic growth rates were compared to determine growth patterns.

Segmentation Analysis:

The Myasthenia Gravis Treatment Market is segmented by Treatment (Revenue, USD Million, 2015 - 2026), End-Use (Revenue, USD Million, 2015 - 2026), Regional (Revenue, USD Million, 2015 - 2026). We are analyzing the market of these segments to identify which segment is the largest now and in the future, which segment has the highest growth rate, and the segment which offers the opportunity in the future.

Myasthenia Gravis Treatment Market Basis Point Share Analysis, 2021 Vs. 2028
BasisPointShareAnalysis
To get detailed analysis on all segments
BUY NOW
  • Based on Treatment (Revenue, USD Million, 2015 - 2026) the market is segmented as, Medication, Surgery, Others
  • Based on End-Use (Revenue, USD Million, 2015 - 2026) the market is segmented as, Hospitals, Clinics, Others
  • Based on Regional (Revenue, USD Million, 2015 - 2026) the market is segmented as, North America, The U.S., Canada, Europe, UK, Germany, France, Italy, Spain, Russia, Asia Pacific, Japan, China, India, South Korea, Singapore, Australia, Latin America, Brazil, Mexico, Argentina, Middle East & Africa, South Africa, Saudi Arabia, UAE, KEY MARKET PLAYERS, Alexion Pharmaceutical Inc., Grifols SA, Avadel Pharmaceuticals plc, Novartis AG, Pfizer, Inc., AbbVie Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Bausch Health Companies Inc.

Regional Analysis:

Myasthenia Gravis Treatment Market is being analyzed by North America, Europe, Asia-Pacific (APAC), Latin America (LATAM), Middle East & Africa (MEA) regions. Key countries including the U.S., Canada, Germany, France, UK, Italy, Spain, China, India, Japan, Brazil, GCC Countries, and South Africa among others were analyzed considering various micro and macro trends.

Myasthenia Gravis Treatment Market Attractiveness Analysis, By Region 2020-2028
AttractivenessAnalysis
To know more about the market opportunities by region and country, click here to
REQUEST FREE CUSTOMIZATION

Myasthenia Gravis Treatment Market : Risk Analysis

SkyQuest's expert analysts have conducted a risk analysis to understand the impact of external extremities on Myasthenia Gravis Treatment Market. We analyzed how geopolitical influence, natural disasters, climate change, legal scenario, economic impact, trade & economic policies, social & ethnic concerns, and demographic changes might affect Myasthenia Gravis Treatment Market's supply chain, distribution, and total revenue growth.

Competitive landscaping:

To understand the competitive landscape, we are analyzing key Myasthenia Gravis Treatment Market vendors in the market. To understand the competitive rivalry, we are comparing the revenue, expenses, resources, product portfolio, region coverage, market share, key initiatives, product launches, and any news related to the Myasthenia Gravis Treatment Market.

To validate our hypothesis and validate our findings on the market ecosystem, we are also conducting a detailed porter's five forces analysis. Competitive Rivalry, Supplier Power, Buyer Power, Threat of Substitution, and Threat of New Entry each force is analyzed by various parameters governing those forces.

Key Players Covered in the Report:

  • rview
  • The global myasthenia gravis (MG) treatment market size was estimated at USD 1.16 billion in 2018 and is anticipated to grow at a CAGR of 7.5% over the forecast period. The key factors driving this market include the rising adoption of immunotherapies, the approval of promising drugs, the emergence of biologics, and increasing awareness of rare diseases.
  • Myasthenia gravis (MG) is a chronic, progressive, and rare neuromuscular disorder that is characterized by weakness of the head, limb, spinal, eye, and respiratory muscles. In this autoimmune disorder, antibodies are produced against the acetylcholine receptor (AchR) that impedes the normal transmission of electrical signals from nerves to muscles.
  • According to the National Organization for Rare Disorders (NORD), in the U.S. around 14-40 per 100,000 individuals suffer from myasthenia gravis. Reports suggest that the frequency of the disorder is on the rise over the last several decades. This can be attributed to the better identification of patients and the increasing prevalence of autoimmune disorders in general across the world.
  • Myasthenia gravis occurs more frequently in females than in males, and although symptoms may appear at any age, its onset usually peaks in men in their 50s or 60s and women during their 20s or 30s. There is no proven cure for myasthenia gravis, however, patients can be treated with medications and surgery for the management of the symptoms.
  • At present, research is focused on a better understanding of the specifics of the autoimmune problems associated with MG and improving their diagnosis and treatment. Additionally, the market is observing a paradigm shift in the area of research from suppressing the immune system to rebalancing it. Another important area of research is the physiology of the neuromuscular junction (NMJ), aimed at improvement in its function regardless of probable immune system attacks.
  • Treatment Insights
  • Among the treatments, medication held the largest market share and is expected to maintain its leading position through the forecast period. This is because medications can dramatically inhibit the immune system and largely manage the associated symptoms. Medications include immunotherapies such as Soliris (eculizumab), corticosteroids, and immunosuppressive drugs such as Prograf (tacrolimus) and Neoral/Sandimmune (cyclosporine). The other major treatment alternative, surgery, is the most invasive in nature and usually involves a thymectomy (thymus removal). The thymus deteriorates with age (thymic involution), however complete loss of the thymus in such manner will significantly weaken a patient’s immune system.
  • The myasthenia gravis treatment market is witnessing an upsurge in the number of pipeline studies for drug development that is expected to drive the market. Recently, Alexion Pharmaceuticals’ Soliris (eculizumab) received approval by both the U.S. FDA and the European Commission for the treatment of adult patients with generalized myasthenia gravis who are anti-AchR antibody-positive. Soliris is the first and only complement inhibitor approved for this disorder. The increasing use of monoclonal antibodies and immunosuppressants is aimed at the reduction of lifelong exposure to corticosteroids and improvement in long-term results.
  • End-Use Insights
  • Based on end-use, the myasthenia gravis treatment market has been segmented into hospitals, clinics, and others. The hospital segment held the largest market share in 2018 and is expected to grow at the highest CAGR over the forecast period. This can be attributed to access to a large patient pool and high demand for advanced equipment for MG treatment in hospital settings. There has been an increase in the number of patient visits for diagnosis and treatment of MG due to the availability of a broad range of treatment options in such facilities. Furthermore, one of the major factors contributing to its large share is the increased investment in state-of-the-art healthcare infrastructures.
  • The clinic segment held the second-largest share in 2018 and is expected to retain the position through the forecast period. Currently, with the growing need for specialized treatments, a lot of patients are preferring specialty clinics for rapid diagnosis and effective MG treatment. A large segment of the end-users also depends on eCommerce channels for obtaining therapeutics for myasthenia gravis. These segments are significantly contributing to the growth of myasthenia gravis treatment market.
  • Regional Insights
  • Among all the regions, North America had the largest market share in 2018 and is projected to lead the market over the forecast period. This can be attributed to the high adoption of immunotherapies and monoclonal antibodies, increasing healthcare expenditure, presence of established research and development facilities, and favorable reimbursement scenario.
  • Asia Pacific is anticipated to grow at the fastest CAGR through the forecast period due to the increase in revenue generation from medications such as immunosuppressants and monoclonal antibodies in this region. Other factors propelling the growth are the initiatives associated with increasing investments in the healthcare sector by the governments and manufacturers in the region.
  • Myasthenia Gravis Treatment Market Share Insights
  • Alexion Pharmaceuticals and Astellas Pharma hold the largest market shares due to the strong sales of their flagship products including Soliris and Prograf.
  • However, generic competition is a major hindrance to market growth, due to patent loss of several marketed products and the availability of low-priced substitutes to branded drugs in the market. To gain an advantage against competitors, companies are adopting strategies such as expansion in the emerging countries, new product development, spreading awareness, and getting into collaborations.
  • KEY MARKET SEGMENTS
  • By Treatment (Revenue, USD Million, 2015 - 2026)
  • Medication
  • Surgery
  • Others
  • By End-Use (Revenue, USD Million, 2015 - 2026)
  • Hospitals
  • Clinics
  • Others
  • By Regional (Revenue, USD Million, 2015 - 2026)
  • North America
  • The U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Singapore
  • Australia
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • KEY MARKET PLAYERS
  • Alexion Pharmaceutical Inc.
  • Grifols SA
  • Avadel Pharmaceuticals plc
  • Novartis AG
  • Pfizer, Inc.
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Bausch Health Companies Inc.
  • Shire plc."

SkyQuest's Expertise:

The Myasthenia Gravis Treatment Market is being analyzed by SkyQuest's analysts with the help of 20+ scheduled Primary interviews from both the demand and supply sides. We have already invested more than 250 hours on this report and are still refining our date to provide authenticated data to your readers and clients. Exhaustive primary and secondary research is conducted to collect information on the market, peer market, and parent market.

Our cross-industry experts and revenue-impact consultants at SkyQuest enable our clients to convert market intelligence into actionable, quantifiable results through personalized engagement.

Scope Of Report

Report Attribute Details
The base year for estimation 2021
Historical data 2016 – 2022
Forecast period 2022 – 2028
Report coverage Revenue forecast, volume forecast, company ranking, competitive landscape, growth factors, and trends, Pricing Analysis
Segments covered
  • By Treatment (Revenue, USD Million, 2015 - 2026) - Medication, Surgery, Others
  • By End-Use (Revenue, USD Million, 2015 - 2026) - Hospitals, Clinics, Others
  • By Regional (Revenue, USD Million, 2015 - 2026) - North America, The U.S., Canada, Europe, UK, Germany, France, Italy, Spain, Russia, Asia Pacific, Japan, China, India, South Korea, Singapore, Australia, Latin America, Brazil, Mexico, Argentina, Middle East & Africa, South Africa, Saudi Arabia, UAE, KEY MARKET PLAYERS, Alexion Pharmaceutical Inc., Grifols SA, Avadel Pharmaceuticals plc, Novartis AG, Pfizer, Inc., AbbVie Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Bausch Health Companies Inc.
Regional scope North America, Europe, Asia-Pacific (APAC), Latin America (LATAM), Middle East & Africa (MEA)
Country scope U.S., Canada, Germany, France, UK, Italy, Spain, China, India, Japan, Brazil, GCC Countries, South Africa
Key companies profiled
  • rview
  • The global myasthenia gravis (MG) treatment market size was estimated at USD 1.16 billion in 2018 and is anticipated to grow at a CAGR of 7.5% over the forecast period. The key factors driving this market include the rising adoption of immunotherapies, the approval of promising drugs, the emergence of biologics, and increasing awareness of rare diseases.
  • Myasthenia gravis (MG) is a chronic, progressive, and rare neuromuscular disorder that is characterized by weakness of the head, limb, spinal, eye, and respiratory muscles. In this autoimmune disorder, antibodies are produced against the acetylcholine receptor (AchR) that impedes the normal transmission of electrical signals from nerves to muscles.
  • According to the National Organization for Rare Disorders (NORD), in the U.S. around 14-40 per 100,000 individuals suffer from myasthenia gravis. Reports suggest that the frequency of the disorder is on the rise over the last several decades. This can be attributed to the better identification of patients and the increasing prevalence of autoimmune disorders in general across the world.
  • Myasthenia gravis occurs more frequently in females than in males, and although symptoms may appear at any age, its onset usually peaks in men in their 50s or 60s and women during their 20s or 30s. There is no proven cure for myasthenia gravis, however, patients can be treated with medications and surgery for the management of the symptoms.
  • At present, research is focused on a better understanding of the specifics of the autoimmune problems associated with MG and improving their diagnosis and treatment. Additionally, the market is observing a paradigm shift in the area of research from suppressing the immune system to rebalancing it. Another important area of research is the physiology of the neuromuscular junction (NMJ), aimed at improvement in its function regardless of probable immune system attacks.
  • Treatment Insights
  • Among the treatments, medication held the largest market share and is expected to maintain its leading position through the forecast period. This is because medications can dramatically inhibit the immune system and largely manage the associated symptoms. Medications include immunotherapies such as Soliris (eculizumab), corticosteroids, and immunosuppressive drugs such as Prograf (tacrolimus) and Neoral/Sandimmune (cyclosporine). The other major treatment alternative, surgery, is the most invasive in nature and usually involves a thymectomy (thymus removal). The thymus deteriorates with age (thymic involution), however complete loss of the thymus in such manner will significantly weaken a patient’s immune system.
  • The myasthenia gravis treatment market is witnessing an upsurge in the number of pipeline studies for drug development that is expected to drive the market. Recently, Alexion Pharmaceuticals’ Soliris (eculizumab) received approval by both the U.S. FDA and the European Commission for the treatment of adult patients with generalized myasthenia gravis who are anti-AchR antibody-positive. Soliris is the first and only complement inhibitor approved for this disorder. The increasing use of monoclonal antibodies and immunosuppressants is aimed at the reduction of lifelong exposure to corticosteroids and improvement in long-term results.
  • End-Use Insights
  • Based on end-use, the myasthenia gravis treatment market has been segmented into hospitals, clinics, and others. The hospital segment held the largest market share in 2018 and is expected to grow at the highest CAGR over the forecast period. This can be attributed to access to a large patient pool and high demand for advanced equipment for MG treatment in hospital settings. There has been an increase in the number of patient visits for diagnosis and treatment of MG due to the availability of a broad range of treatment options in such facilities. Furthermore, one of the major factors contributing to its large share is the increased investment in state-of-the-art healthcare infrastructures.
  • The clinic segment held the second-largest share in 2018 and is expected to retain the position through the forecast period. Currently, with the growing need for specialized treatments, a lot of patients are preferring specialty clinics for rapid diagnosis and effective MG treatment. A large segment of the end-users also depends on eCommerce channels for obtaining therapeutics for myasthenia gravis. These segments are significantly contributing to the growth of myasthenia gravis treatment market.
  • Regional Insights
  • Among all the regions, North America had the largest market share in 2018 and is projected to lead the market over the forecast period. This can be attributed to the high adoption of immunotherapies and monoclonal antibodies, increasing healthcare expenditure, presence of established research and development facilities, and favorable reimbursement scenario.
  • Asia Pacific is anticipated to grow at the fastest CAGR through the forecast period due to the increase in revenue generation from medications such as immunosuppressants and monoclonal antibodies in this region. Other factors propelling the growth are the initiatives associated with increasing investments in the healthcare sector by the governments and manufacturers in the region.
  • Myasthenia Gravis Treatment Market Share Insights
  • Alexion Pharmaceuticals and Astellas Pharma hold the largest market shares due to the strong sales of their flagship products including Soliris and Prograf.
  • However, generic competition is a major hindrance to market growth, due to patent loss of several marketed products and the availability of low-priced substitutes to branded drugs in the market. To gain an advantage against competitors, companies are adopting strategies such as expansion in the emerging countries, new product development, spreading awareness, and getting into collaborations.
  • KEY MARKET SEGMENTS
  • By Treatment (Revenue, USD Million, 2015 - 2026)
  • Medication
  • Surgery
  • Others
  • By End-Use (Revenue, USD Million, 2015 - 2026)
  • Hospitals
  • Clinics
  • Others
  • By Regional (Revenue, USD Million, 2015 - 2026)
  • North America
  • The U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Singapore
  • Australia
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • KEY MARKET PLAYERS
  • Alexion Pharmaceutical Inc.
  • Grifols SA
  • Avadel Pharmaceuticals plc
  • Novartis AG
  • Pfizer, Inc.
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Bausch Health Companies Inc.
  • Shire plc."
Customization scope Free report customization (15% Free customization) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options Reap the benefits of customized purchase options to fit your specific research requirements.

Objectives of the Study

  • To forecast the market size, in terms of value, for various segments with respect to five main regions, namely, North America, Europe, Asia-Pacific (APAC), Latin America (LATAM), Middle East & Africa (MEA)
  • To provide detailed information regarding the major factors influencing the growth of the Market (drivers, restraints, opportunities, and challenges)
  • To strategically analyze the micro markets with respect to the individual growth trends, future prospects, and contribution to the total market
  • To provide a detailed overview of the value chain and analyze market trends with the Porter's five forces analysis
  • To analyze the opportunities in the market for various stakeholders by identifying the high-growth Segments
  • To identify the key players and comprehensively analyze their market position in terms of ranking and core competencies, along with detailing the competitive landscape for the market leaders
  • To analyze competitive development such as joint ventures, mergers and acquisitions, new product launches and development, and research and development in the market

What does this Report Deliver?

  • Market Estimation for 20+ Countries
  • Historical data coverage: 2016 to 2022
  • Growth projections: 2022 to 2028
  • SkyQuest's premium market insights: Innovation matrix, IP analysis, Production Analysis, Value chain analysis, Technological trends, and Trade analysis
  • Customization on Segments, Regions, and Company Profiles
  • 100+ tables, 150+ Figures, 10+ matrix
  • Global and Country Market Trends
  • Comprehensive Mapping of Industry Parameters
  • Attractive Investment Proposition
  • Competitive Strategies Adopted by Leading Market Participants
  • Market drivers, restraints, opportunities, and its impact on the market
  • Regulatory scenario, regional dynamics, and insights of leading countries in each region
  • Segment trends analysis, opportunity, and growth
  • Opportunity analysis by region and country
  • Porter's five force analysis to know the market's condition
  • Pricing analysis
  • Parent market analysis
  • Product portfolio benchmarking

Table Of Content

Executive Summary

Market overview

  • Exhibit: Executive Summary – Chart on Market Overview
  • Exhibit: Executive Summary – Data Table on Market Overview
  • Exhibit: Executive Summary – Chart on Myasthenia Gravis Treatment Market Characteristics
  • Exhibit: Executive Summary – Chart on Market by Geography
  • Exhibit: Executive Summary – Chart on Market Segmentation
  • Exhibit: Executive Summary – Chart on Incremental Growth
  • Exhibit: Executive Summary – Data Table on Incremental Growth
  • Exhibit: Executive Summary – Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • SWOT Analysis

KEY MARKET INSIGHTS

  • Technology Analysis
    • (Exhibit: Data Table: Name of technology and details)
  • Pricing Analysis
    • (Exhibit: Data Table: Name of technology and pricing details)
  • Supply Chain Analysis
    • (Exhibit: Detailed Supply Chain Presentation)
  • Value Chain Analysis
    • (Exhibit: Detailed Value Chain Presentation)
  • Ecosystem Of the Market
    • Exhibit: Parent Market Ecosystem Market Analysis
    • Exhibit: Market Characteristics of Parent Market
  • IP Analysis
    • (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
  • Trade Analysis
    • (Exhibit: Data Table: Import and Export data details)
  • Startup Analysis
    • (Exhibit: Data Table: Emerging startups details)
  • Raw Material Analysis
    • (Exhibit: Data Table: Mapping of key raw materials)
  • Innovation Matrix
    • (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
  • Pipeline product Analysis
    • (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
  • Macroeconomic Indicators

COVID IMPACT

  • Introduction
  • Impact On Economy—scenario Assessment
    • Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
  • Revised Market Size
    • Exhibit: Data Table on Myasthenia Gravis Treatment Market size and forecast 2021-2027 ($ million)
  • Impact Of COVID On Key Segments
    • Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
  • COVID Strategies By Company
    • Exhibit: Analysis on key strategies adopted by companies

MARKET DYNAMICS & OUTLOOK

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • Regulatory Landscape
    • Exhibit: Data Table on regulation from different region
  • SWOT Analysis
  • Porters Analysis
    • Competitive rivalry
      • Exhibit: Competitive rivalry Impact of key factors, 2021
    • Threat of substitute products
      • Exhibit: Threat of Substitute Products Impact of key factors, 2021
    • Bargaining power of buyers
      • Exhibit: buyers bargaining power Impact of key factors, 2021
    • Threat of new entrants
      • Exhibit: Threat of new entrants Impact of key factors, 2021
    • Bargaining power of suppliers
      • Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
  • Skyquest special insights on future disruptions
    • Political Impact
    • Economic impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Market Size by Region

  • Chart on Market share by geography 2021-2027 (%)
  • Data Table on Market share by geography 2021-2027(%)
  • North America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • USA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Canada
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Europe
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Germany
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Spain
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • France
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • UK
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Europe
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Asia Pacific
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • China
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • India
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Japan
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Korea
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Asia Pacific
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Latin America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Brazil
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of South America
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Middle East & Africa (MEA)
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • GCC Countries
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Africa
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of MEA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)

KEY COMPANY PROFILES

  • Competitive Landscape
    • Total number of companies covered
      • Exhibit: companies covered in the report, 2021
    • Top companies market positioning
      • Exhibit: company positioning matrix, 2021
    • Top companies market Share
      • Exhibit: Pie chart analysis on company market share, 2021(%)
  • rview
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • The global myasthenia gravis (MG) treatment market size was estimated at USD 1.16 billion in 2018 and is anticipated to grow at a CAGR of 7.5% over the forecast period. The key factors driving this market include the rising adoption of immunotherapies, the approval of promising drugs, the emergence of biologics, and increasing awareness of rare diseases.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Myasthenia gravis (MG) is a chronic, progressive, and rare neuromuscular disorder that is characterized by weakness of the head, limb, spinal, eye, and respiratory muscles. In this autoimmune disorder, antibodies are produced against the acetylcholine receptor (AchR) that impedes the normal transmission of electrical signals from nerves to muscles.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • According to the National Organization for Rare Disorders (NORD), in the U.S. around 14-40 per 100,000 individuals suffer from myasthenia gravis. Reports suggest that the frequency of the disorder is on the rise over the last several decades. This can be attributed to the better identification of patients and the increasing prevalence of autoimmune disorders in general across the world.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Myasthenia gravis occurs more frequently in females than in males, and although symptoms may appear at any age, its onset usually peaks in men in their 50s or 60s and women during their 20s or 30s. There is no proven cure for myasthenia gravis, however, patients can be treated with medications and surgery for the management of the symptoms.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • At present, research is focused on a better understanding of the specifics of the autoimmune problems associated with MG and improving their diagnosis and treatment. Additionally, the market is observing a paradigm shift in the area of research from suppressing the immune system to rebalancing it. Another important area of research is the physiology of the neuromuscular junction (NMJ), aimed at improvement in its function regardless of probable immune system attacks.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Treatment Insights
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Among the treatments, medication held the largest market share and is expected to maintain its leading position through the forecast period. This is because medications can dramatically inhibit the immune system and largely manage the associated symptoms. Medications include immunotherapies such as Soliris (eculizumab), corticosteroids, and immunosuppressive drugs such as Prograf (tacrolimus) and Neoral/Sandimmune (cyclosporine). The other major treatment alternative, surgery, is the most invasive in nature and usually involves a thymectomy (thymus removal). The thymus deteriorates with age (thymic involution), however complete loss of the thymus in such manner will significantly weaken a patient’s immune system.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • The myasthenia gravis treatment market is witnessing an upsurge in the number of pipeline studies for drug development that is expected to drive the market. Recently, Alexion Pharmaceuticals’ Soliris (eculizumab) received approval by both the U.S. FDA and the European Commission for the treatment of adult patients with generalized myasthenia gravis who are anti-AchR antibody-positive. Soliris is the first and only complement inhibitor approved for this disorder. The increasing use of monoclonal antibodies and immunosuppressants is aimed at the reduction of lifelong exposure to corticosteroids and improvement in long-term results.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • End-Use Insights
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Based on end-use, the myasthenia gravis treatment market has been segmented into hospitals, clinics, and others. The hospital segment held the largest market share in 2018 and is expected to grow at the highest CAGR over the forecast period. This can be attributed to access to a large patient pool and high demand for advanced equipment for MG treatment in hospital settings. There has been an increase in the number of patient visits for diagnosis and treatment of MG due to the availability of a broad range of treatment options in such facilities. Furthermore, one of the major factors contributing to its large share is the increased investment in state-of-the-art healthcare infrastructures.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • The clinic segment held the second-largest share in 2018 and is expected to retain the position through the forecast period. Currently, with the growing need for specialized treatments, a lot of patients are preferring specialty clinics for rapid diagnosis and effective MG treatment. A large segment of the end-users also depends on eCommerce channels for obtaining therapeutics for myasthenia gravis. These segments are significantly contributing to the growth of myasthenia gravis treatment market.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Regional Insights
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Among all the regions, North America had the largest market share in 2018 and is projected to lead the market over the forecast period. This can be attributed to the high adoption of immunotherapies and monoclonal antibodies, increasing healthcare expenditure, presence of established research and development facilities, and favorable reimbursement scenario.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Asia Pacific is anticipated to grow at the fastest CAGR through the forecast period due to the increase in revenue generation from medications such as immunosuppressants and monoclonal antibodies in this region. Other factors propelling the growth are the initiatives associated with increasing investments in the healthcare sector by the governments and manufacturers in the region.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Myasthenia Gravis Treatment Market Share Insights
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Alexion Pharmaceuticals and Astellas Pharma hold the largest market shares due to the strong sales of their flagship products including Soliris and Prograf.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • However, generic competition is a major hindrance to market growth, due to patent loss of several marketed products and the availability of low-priced substitutes to branded drugs in the market. To gain an advantage against competitors, companies are adopting strategies such as expansion in the emerging countries, new product development, spreading awareness, and getting into collaborations.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • KEY MARKET SEGMENTS
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • By Treatment (Revenue, USD Million, 2015 - 2026)
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Medication
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Surgery
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Others
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • By End-Use (Revenue, USD Million, 2015 - 2026)
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Hospitals
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Clinics
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Others
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • By Regional (Revenue, USD Million, 2015 - 2026)
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • North America
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • The U.S.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Canada
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Europe
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • UK
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Germany
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • France
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Italy
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Spain
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Russia
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Asia Pacific
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Japan
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • China
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • India
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • South Korea
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Singapore
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Australia
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Latin America
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Brazil
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Mexico
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Argentina
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Middle East & Africa
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • South Africa
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Saudi Arabia
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • UAE
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • KEY MARKET PLAYERS
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Alexion Pharmaceutical Inc.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Grifols SA
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Avadel Pharmaceuticals plc
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Novartis AG
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Pfizer, Inc.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • AbbVie Inc.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • F. Hoffmann-La Roche Ltd.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • GlaxoSmithKline plc
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Bausch Health Companies Inc.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Shire plc."
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments

Methodology

For the Myasthenia Gravis Treatment Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:

1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.

2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Myasthenia Gravis Treatment Market.

3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.

4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.

Analyst Support

Customization Options

With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Myasthenia Gravis Treatment Market:

Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.

Regional Analysis: Further analysis of the Myasthenia Gravis Treatment Market for additional countries.

Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.

Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.

Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.

Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.

Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.

Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.

$5,300
BUY NOW

REQUEST FOR SAMPLE

Want to customize this report?
REQUEST FREE CUSTOMIZATION

FAQs

The market for Myasthenia Gravis Treatment was estimated to be valued at US$ XX Mn in 2021.

The Myasthenia Gravis Treatment Market is estimated to grow at a CAGR of XX% by 2028.

The Myasthenia Gravis Treatment Market is segmented on the basis of Treatment (Revenue, USD Million, 2015 - 2026), End-Use (Revenue, USD Million, 2015 - 2026), Regional (Revenue, USD Million, 2015 - 2026).

Based on region, the Myasthenia Gravis Treatment Market is segmented into North America, Europe, Asia Pacific, Middle East & Africa and Latin America.

The key players operating in the Myasthenia Gravis Treatment Market are rview , The myasthenia gravis (MG) treatment market size was estimated at USD 1.16 billion in 2018 and is anticipated to grow at a CAGR of 7.5% over the forecast period. The key factors driving this market include the rising adoption of immunotherapies, the approval of promising drugs, the emergence of biologics, and increasing awareness of rare diseases. , Myasthenia gravis (MG) is a chronic, progressive, and rare neuromuscular disorder that is characterized by weakness of the head, limb, spinal, eye, and respiratory muscles. In this autoimmune disorder, antibodies are produced against the acetylcholine receptor (AchR) that impedes the normal transmission of electrical signals from nerves to muscles. , According to the National Organization for Rare Disorders (NORD), in the U.S. around 14-40 per 100,000 individuals suffer from myasthenia gravis. Reports suggest that the frequency of the disorder is on the rise over the last several decades. This can be attributed to the better identification of patients and the increasing prevalence of autoimmune disorders in general across the world. , Myasthenia gravis occurs more frequently in females than in males, and although symptoms may appear at any age, its onset usually peaks in men in their 50s or 60s and women during their 20s or 30s. There is no proven cure for myasthenia gravis, however, patients can be treated with medications and surgery for the management of the symptoms. , At present, research is focused on a better understanding of the specifics of the autoimmune problems associated with MG and improving their diagnosis and treatment. Additionally, the market is observing a paradigm shift in the area of research from suppressing the immune system to rebalancing it. Another important area of research is the physiology of the neuromuscular junction (NMJ), aimed at improvement in its function regardless of probable immune system attacks. , Treatment Insights , Among the treatments, medication held the largest market share and is expected to maintain its leading position through the forecast period. This is because medications can dramatically inhibit the immune system and largely manage the associated symptoms. Medications include immunotherapies such as Soliris (eculizumab), corticosteroids, and immunosuppressive drugs such as Prograf (tacrolimus) and Neoral/Sandimmune (cyclosporine). The other major treatment alternative, surgery, is the most invasive in nature and usually involves a thymectomy (thymus removal). The thymus deteriorates with age (thymic involution), however complete loss of the thymus in such manner will significantly weaken a patient’s immune system. , The myasthenia gravis treatment market is witnessing an upsurge in the number of pipeline studies for drug development that is expected to drive the market. Recently, Alexion Pharmaceuticals’ Soliris (eculizumab) received approval by both the U.S. FDA and the European Commission for the treatment of adult patients with generalized myasthenia gravis who are anti-AchR antibody-positive. Soliris is the first and only complement inhibitor approved for this disorder. The increasing use of monoclonal antibodies and immunosuppressants is aimed at the reduction of lifelong exposure to corticosteroids and improvement in long-term results. , End-Use Insights , Based on end-use, the myasthenia gravis treatment market has been segmented into hospitals, clinics, and others. The hospital segment held the largest market share in 2018 and is expected to grow at the highest CAGR over the forecast period. This can be attributed to access to a large patient pool and high demand for advanced equipment for MG treatment in hospital settings. There has been an increase in the number of patient visits for diagnosis and treatment of MG due to the availability of a broad range of treatment options in such facilities. Furthermore, one of the major factors contributing to its large share is the increased investment in state-of-the-art healthcare infrastructures. , The clinic segment held the second-largest share in 2018 and is expected to retain the position through the forecast period. Currently, with the growing need for specialized treatments, a lot of patients are preferring specialty clinics for rapid diagnosis and effective MG treatment. A large segment of the end-users also depends on eCommerce channels for obtaining therapeutics for myasthenia gravis. These segments are significantly contributing to the growth of myasthenia gravis treatment market. , Regional Insights , Among all the regions, North America had the largest market share in 2018 and is projected to lead the market over the forecast period. This can be attributed to the high adoption of immunotherapies and monoclonal antibodies, increasing healthcare expenditure, presence of established research and development facilities, and favorable reimbursement scenario. , Asia Pacific is anticipated to grow at the fastest CAGR through the forecast period due to the increase in revenue generation from medications such as immunosuppressants and monoclonal antibodies in this region. Other factors propelling the growth are the initiatives associated with increasing investments in the healthcare sector by the governments and manufacturers in the region. , Myasthenia Gravis Treatment Market Share Insights , Alexion Pharmaceuticals and Astellas Pharma hold the largest market shares due to the strong sales of their flagship products including Soliris and Prograf. , However, generic competition is a major hindrance to market growth, due to patent loss of several marketed products and the availability of low-priced substitutes to branded drugs in the market. To gain an advantage against competitors, companies are adopting strategies such as expansion in the emerging countries, new product development, spreading awareness, and getting into collaborations. , KEY MARKET SEGMENTS, By Treatment (Revenue, USD Million, 2015 - 2026) , Medication , Surgery , Others , By End-Use (Revenue, USD Million, 2015 - 2026) , Hospitals , Clinics , Others , By Regional (Revenue, USD Million, 2015 - 2026) , North America , The U.S. , Canada , Europe , UK , Germany , France , Italy , Spain , Russia , Asia Pacific , Japan , China , India , South Korea , Singapore , Australia , Latin America , Brazil , Mexico , Argentina , Middle East & Africa , South Africa , Saudi Arabia , UAE , KEY MARKET PLAYERS, Alexion Pharmaceutical Inc. , Grifols SA , Avadel Pharmaceuticals plc , Novartis AG , Pfizer, Inc. , AbbVie Inc. , F. Hoffmann-La Roche Ltd. , GlaxoSmithKline plc , Bausch Health Companies Inc. , Shire plc.".

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Related Reports

Paresthesia Treatment Market
Buy Now GET FREE SAMPLE
Obesity Treatment Market
Buy Now GET FREE SAMPLE
Cellulite Treatment Market
Buy Now GET FREE SAMPLE
Hyperhidrosis Treatment Market
Buy Now GET FREE SAMPLE
Fibromyalgia Treatment Market
Buy Now GET FREE SAMPLE
Thyroid Gland Disorders Treatment Market
Buy Now GET FREE SAMPLE
Dry Eye Syndrome Treatment Market
Buy Now GET FREE SAMPLE
Enzyme Replacement Therapy Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Myasthenia Gravis Treatment Market

Report ID: UCMIG35I2237

sales@skyquestt.com
USA +1 351-333-4748

BUY NOW GET FREE SAMPLE